121 related articles for article (PubMed ID: 8764248)
1. Bradykinin pathway is involved in acute hemodynamic effects of enalaprilat in dogs with heart failure.
Barbe F; Su JB; Guyene TT; Crozatier B; Ménard J; Hittinger L
Am J Physiol; 1996 Jun; 270(6 Pt 2):H1985-92. PubMed ID: 8764248
[TBL] [Abstract][Full Text] [Related]
2. Preserved vasodilator effect of bradykinin in dogs with heart failure.
Su JB; Barbe F; Houel R; Guyene TT; Crozatier B; Hittinger L
Circulation; 1998 Dec 22-29; 98(25):2911-8. PubMed ID: 9860795
[TBL] [Abstract][Full Text] [Related]
3. Comparison between angiotensin receptor antagonism and converting enzyme inhibition in heart failure. Differential acute effects according to the renin-angiotensin system activation.
Su J; Barbe F; Houël R; Guyene TT; Crozatier B; Hittinger L
Basic Res Cardiol; 1999 Apr; 94(2):128-35. PubMed ID: 10326661
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism.
Nikolaidis LA; Doverspike A; Huerbin R; Hentosz T; Shannon RP
Circulation; 2002 Jun; 105(23):2785-90. PubMed ID: 12057995
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism in conscious pigs with congestive heart failure.
Shen YT; Wiedmann RT; Greenland BD; Lynch JJ; Grossman W
Cardiovasc Res; 1998 Aug; 39(2):413-22. PubMed ID: 9798526
[TBL] [Abstract][Full Text] [Related]
6. Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure.
Su JB; Barbe F; Crozatier B; Campbell DJ; Hittinger L
J Cardiovasc Pharmacol; 1999 Nov; 34(5):700-10. PubMed ID: 10547087
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of the dual metallopeptidase inhibitor, MDL 100,240 and of enalaprilat on regional and on cardiac haemodynamics in conscious, hypertensive, transgenic ((mRen-2)27) rats.
Gardiner SM; Kemp PA; Brunner-Ferber F; Bennett T
Br J Pharmacol; 1997 Dec; 122(8):1694-701. PubMed ID: 9422816
[TBL] [Abstract][Full Text] [Related]
8. The haemodynamic effects of two angiotensin converting enzyme inhibitors, enalaprilat and zofenoprilat, in the rat: evidence for the involvement of bradykinin.
Tio RA; Heiligers JP; de Langen CD; van Gilst WH; König W; Saxena PR; Wesseling H
J Hypertens Suppl; 1989 Dec; 7(6):S296-7. PubMed ID: 2561143
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin.
Pretorius M; Rosenbaum D; Vaughan DE; Brown NJ
Circulation; 2003 Feb; 107(4):579-85. PubMed ID: 12566370
[TBL] [Abstract][Full Text] [Related]
10. Bradykinin contribution to renal blood flow effect of angiotensin converting enzyme inhibitor in the conscious sodium-restricted dog.
Zimmerman BG; Raich PC; Vavrek RJ; Stewart JM
Circ Res; 1990 Jan; 66(1):234-40. PubMed ID: 2153061
[TBL] [Abstract][Full Text] [Related]
11. Potentiation by enalaprilat of fenoldopam-evoked natriuresis is due to blockade of intrarenal production of angiotensin-II in rats.
Chen C; Lokhandwala MF
Naunyn Schmiedebergs Arch Pharmacol; 1995 Aug; 352(2):194-200. PubMed ID: 7477443
[TBL] [Abstract][Full Text] [Related]
12. Endogenous angiotensin II and bradykinin delay and attenuate the hypotension after N-type calcium channel blockade in conscious rabbits.
Whorlow SL; Angus JA; Wright CE
J Cardiovasc Pharmacol; 1998 Dec; 32(6):951-61. PubMed ID: 9869501
[TBL] [Abstract][Full Text] [Related]
13. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition.
Kiowski W; Beermann J; Rickenbacher P; Haemmerli R; Thomas M; Burkart F; Meinertz T
Circulation; 1994 Dec; 90(6):2748-56. PubMed ID: 7994817
[TBL] [Abstract][Full Text] [Related]
14. Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure.
Evans MA; Burnett JC; Redfield MM
J Am Coll Cardiol; 1995 May; 25(6):1445-50. PubMed ID: 7722147
[TBL] [Abstract][Full Text] [Related]
15. Role of kinins in the renal response to enalaprilat in normotensive and hypertensive rats.
Fitzgibbon WR; Jaffa AA; Mayfield RK; Ploth DW
Hypertension; 1996 Feb; 27(2):235-44. PubMed ID: 8567046
[TBL] [Abstract][Full Text] [Related]
16. Acute hemodynamic effects of ciprokiren, a novel renin inhibitor, in sodium-depleted dogs.
Clozel JP; Véniant M; Sprecher U; Fischli W
J Cardiovasc Pharmacol; 1995 Oct; 26(4):674-7. PubMed ID: 8569232
[TBL] [Abstract][Full Text] [Related]
17. Acute hemodynamic effects of the active metabolite of imidapril, (4S)-3-((2S)-2-[N-((1S)-1-carboxy-3-phenyl-propyl)amino]propionyl)-1- methyl-2-oxoimidazolidine-4-carboxylic acid, and enalaprilat in anesthetized dogs.
Ikeo T; Yabana H; Kurosawa H; Kaburaki M; Kikkawa K; Narita H; Murata S; Yamaguchi I
Arzneimittelforschung; 1992 Sep; 42(9):1109-14. PubMed ID: 1332727
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-(1-7) potentiates responses to bradykinin but does not change responses to angiotensin I.
Greco AJ; Master RG; Fokin A; Baber SR; Kadowitz PJ
Can J Physiol Pharmacol; 2006 Nov; 84(11):1163-75. PubMed ID: 17218981
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects.
Laubie M; Schiavi P; Vincent M; Schmitt H
J Cardiovasc Pharmacol; 1984; 6(6):1076-82. PubMed ID: 6084763
[TBL] [Abstract][Full Text] [Related]
20. Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
Trippodo NC; Panchal BC; Fox M
J Pharmacol Exp Ther; 1995 Feb; 272(2):619-27. PubMed ID: 7853175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
